D. Tan

发表

Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.

T. Mok, S. Peters, F. de Marinis, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A practical and adaptive approach to lung cancer screening: a review of international evidence and position on CT lung cancer screening in the Singaporean population by the College of Radiologists Singapore.

A. Poh, G. Kaw, F. Cheah, 2019, Singapore medical journal.

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

Jacob Josiah Santiago Alvarez, W. Tam, A. Takano, 2022, JTO clinical and research reports.

Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer

S. Ong, J. So, K. Foo, 2016, BMJ open gastroenterology.

Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia.

Jie Yang, S. Toyooka, Y. Yatabe, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia

Jie Yang, S. Toyooka, Y. Yatabe, 2022 .

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.

L. Sequist, E. Smit, Gregory Riely, 2022, European journal of cancer.

Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors

A. Shaw, E. Felip, A. Santoro, 2012 .

Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group

J. Chiu, I. Tan, B. Tran, 2023, ESMO open.

CheckMate 73 L: A phase 3 study comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab ± ipilimumab versus concurrent chemoradiotherapy followed by durvalumab for previously untreated, locally advanced stage III non-small cell lung cancer

D. de Ruysscher, S. Ramalingam, J. Urbanic, 2021, Pneumologie.

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

A. Drilon, M. Burkard, T. Owonikoko, 2020, The New England journal of medicine.

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer.

F. Hodi, S. Gettinger, T. Mok, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

B11 Accurate Detection of METex14 Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study

H. Groen, E. Smit, R. Heist, 2020, Journal of Thoracic Oncology.